LIF and neoplasm: To estimate the effect of inhibiting LIF in a model, which reflects tumor heterogeneity in patients, we next tested LIF-neutralizing antibody in patient-derived xenografts (PDXs), which expressed detectable LIF protein (Fig. 4f, g, Supplementary Fig. 4).